StockData
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp (SLXN) company profile

SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.44−0.21 (-12.73%)

Close on Nov 18, 2026Market cap $868.40KP/E –Yield –

About Silexion Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on oncology, specifically developing proprietary therapies for cancers driven by Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations. The company's technology silences oncogenes using chemically modified small interfering RNA (siRNA) constructs that prompt cancer cells to degrade messenger RNA. Its lead product candidate, SIL204, is a second-generation siRNA designed to halt the production of mutated KRAS proteins. SIL204 is administered both intratumorally and systemically via subcutaneous injection in combination with standard chemotherapy to treat patients with locally advanced pancreatic cancer.

The company operates primarily through its subsidiary, Silexion Therapeutics Ltd., in Israel, with operations and corporate entities connected to the Cayman Islands. Its principal executive offices and headquarters are located in Ramat-Gan, Israel. Silexion Therapeutics Corp does not generate commercial product sales and relies on third-party organizations to conduct preclinical and clinical trials and provide manufacturing capabilities.

Summary of the business section of Silexion Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Silexion Therapeutics Corp
Founded
2024
Headquarters
Ramat Gan, L3
Address
12 Abba Hillel Road 5250606
Phone
972-8-6286005
Employees
14, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
E9
Fiscal year ends
December 31
Auditor
Kesselman & Kesselman, Tel-Aviv, Israel

Stock & identifiers

Ticker
SLXN
Other tickers
SLXNW
Exchange
Nasdaq
IPO date
Jan 17, 2025
Shares outstanding
6M, Aug 13, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-10 reverse, May 29, 2026; 1-for-135 reverse, Aug 12, 2025; 1-for-15 reverse, Jul 29, 2025
SEC CIK
2022416
FIGI
BBG01PBJB8C6
Share class FIGI
BBG01PBJB8F3
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ilan HadarChairman and CEO, Director16,547
Mitchell ShirvanCSO and CDO8,789
Hadar Mirit HorenshteinCFO and Secretary12,515
Shlomo NoyDirector25,399
Amnon PeledDirector8,237
Ruth AlonDirector10,228
Avner LushiDirector25,399
Dror Yosef AbramovDirector10,180
Ilan LevinDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 17, 2025
Offer price
$1.35
Exchange
Nasdaq
Lock-up ends (est.)
Jul 16, 2025

“rp, a Cayman Islands exempted company (“New Silexion”, the “Company”, “our company”, “we” or “us”), together with 3,703,703 ordinary warrants to purchase up to 3,703,703 ordinary shares at the public offering price of $1.35 per share and ordinary warrant pursuant to this prospectus.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date of this Annual Report, we have thirteen full-time and one part-time employees. All of our employees are based in Israel. None of our employees is represented by labor unions or covered by collectiv”

Corporate history

Events identified from SEC filings

See a number that looks wrong?